Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Multi-center, Placebo-controlled, Phase III Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2 Add-on to Metformin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin and Sitagliptin Combination Therapy

NCT07076056 is registered in ClinicalTrials.gov with Daewon Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07076056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07076056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Multi-center, Placebo-controlled, Phase III Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2 Add-on to Metformin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin and Sitagliptin Combination Therapy
Lead sponsor
Daewon Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
October 27, 2022
Completion date
June 19, 2024
Enrollment
230 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes